Evidence map›Paper›PMID 41574226›Full record

ArticleAddictive behaviors reports2026

E-liquid flavor alters nicotine exposure, puff topography, and subjective effects under

Arit M Harvanko, Conor A Ruzycki, Jacob McDonald, Eric D Claus, Megan Schroeder, Carolina Ramôa

Abstract read
In one paragraph

Article in Addictive behaviors reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arit M HarvankoFood and Drug Administration, Center for Tobacco Products, Office of Science, 10903 New Hampshire Avenue, Building 71, Room G335, Silver Spring, MD 20993-0002, United States.
Conor A RuzyckiLovelace Biomedical Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, NM 87108-5127, United States.
Jacob McDonaldLovelace Biomedical Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, NM 87108-5127, United States.
Eric D ClausThe Pennsylvania State University, 201 Old Main, University Park, PA 16802, United States.
Megan SchroederFood and Drug Administration, Center for Tobacco Products, Office of Science, 10903 New Hampshire Avenue, Building 71, Room G335, Silver Spring, MD 20993-0002, United States.
Carolina RamôaFood and Drug Administration, Center for Tobacco Products, Office of Science, 10903 New Hampshire Avenue, Building 71, Room G335, Silver Spring, MD 20993-0002, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Electronic nicotine delivery systems (ENDS) are most often used with e-liquids having fruit, and menthol or mint flavor, with tobacco flavor being least prevalent. This study evaluated the effect of a tobacco, fruit, and menthol e-liquid flavor on ENDS abuse liability. Methods: Fifty-two regular ENDS users participated in a double-blinded, randomized, crossover-design study. Study conditions were ENDS (KangerTech CUPTI) with tobacco, menthol, or fruit flavor e-liquids with 1.2 % (all flavors) or 0 % (fruit only) freebase nicotine concentration. On separate days participants used the study products for 10 prescribed puffs and 1 h of Results: Following Conclusions: Tobacco flavor ENDS were rated lower on liking, and associated with less nicotine exposure and fewer puffs taken, but comparably attenuated withdrawal symptoms to other flavor ENDS, while the non-nicotine fruit flavor did not affect withdrawal symptoms.

Indexed as

Behavioral pharmacologyClinical pharmacologyElectronic cigaretteENDSFlavors

Identifiers

PMID41574226
PMCPMC12819110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.